Cure8 research brief
The criteria were tested specifically in patients with psoriasis, uveitis, or IBD presenting with chronic back pain—groups at higher risk of axSpA—so results inform how well the new criteria perform in these real‑world referral populations.
Clinicians (rheumatology, gastroenterology, dermatology, ophthalmology), researchers studying axSpA classification, and patients with IBD or related immune conditions who have chronic back pain.
This multicenter Canadian inception cohort (SASPIC) tested the revised axSpA criteria against rheumatologist diagnosis at staged assessments including clinical exam, labs (HLA‑B27, CRP), radiographs, and MRI. The criteria showed high specificity (≈98–100%) with more modest sensitivity (~53–63%) overall and within the PsO, AAU, and IBD subgroups.
MRI scans were centrally read and used in analyses.
This curation is based on the article abstract (structured content depth: abstract). The study reports diagnostic performance metrics (sensitivity/specificity) using rheumatologist diagnosis as the reference and centralized MRI reading. It evaluates classification accuracy rather than clinical outcomes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
